Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Novartis will pay the English firm Oxford BioMedica $14 million up front and possibly $90 million more over the next three years for a nonexclusive license to OXB’s viral vector technology. OXB will manufacture gene-carrying vectors for Novartis. Novartis, in turn, will use OXB’s technology to insert the instructions for a chimeric antigen receptor into the white blood cells known as T cells. T cells, so enhanced to home in on cancer, are the basis of a Novartis immunotherapy called CTL019/CART-019 (C&EN, Oct. 6, page 12).
This article has been sent to the following recipient: